KIR haplotypes, HLA ligands for KIRs, and combinations of KIR and HLA were investigated in 35 patients with HER2-positive locally advanced BC patients treated with trastuzumab both given as NC together with paclitaxel, and for 1 year after surgery. Here, KIR3DL1 is linked to breast cancer.